How Much Does Polygenic Risk Score Test Cost?

Published on August 7, 2025 | Prices Last Reviewed for Freshness: February 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

A polygenic risk score (PRS) test analyses hundreds to millions of DNA variants to generate a personal risk score for conditions such as heart disease, diabetes, cancer or glaucoma. Our data shows that shoppers focus on one thing first: cost. Prices range from $0 upload tools to $1,700+ premium multi‑disease panels, so understanding the spread matters before paying any fee.

Article Insights

• $0–$100 upload tools exist but skip clinical validation.
• Hospital PRS averages $250 with doctor review.
• Niche kits such as SightScore reach $475 for specialised screening.
• Multi‑disease bundles run $1,000–$1,700+ and include counselling.
• Economic studies find PRS cost‑neutral around $330.
• Future insurance coverage depends on continued evidence.

How Much Does Polygenic Risk Score Test Cost?

The cost of a valid Polygenic Risk Score Test varies from $199 to $1,700+.

A polygenic score differs from single‑gene screens because it aggregates many small genetic effects to improve prediction. Clinical teams now use PRS to fine‑tune health plans, while consumer upload sites satisfy early adopters who want fast insight. Most insurance plans still exclude PRS, making out‑of‑pocket expense the decisive factor. Cardiologist Dr Amit Khera (Mass General Hospital) notes, “Polygenic scores move preventive care upstream, but affordability decides uptake.”

The cost of a Polygenic Risk Score (PRS) test in the US typically ranges around $70 for genotyping alone, based on cost-effectiveness analyses published in recent studies. One detailed economic analysis modeled genotyping costs at about $70 to determine cost-effectiveness for cardiovascular disease risk prediction, showing this as a reasonable current market price for such genetic testing, although prices can vary depending on provider and test comprehensiveness.

Some scenarios envision extremely reduced costs near $0 for individuals who have existing genetic data from direct-to-consumer testing or previous medical testing, which can improve affordability when combined with PRS calculations.

Typical Clinical PRS Test Costs in the U.S.

NorthShore/Endeavor Health lists a single‑condition clinical PRS for $250 with physician interpretation included. Allelica and several hospital‑linked labs benchmark similar price points, keeping the provider cost predictable across states. No current insurance codes offset that expense, so patients should budget the entire fee.

Consumer or Budget Options

Upload‑only calculators slash the price because they reuse raw genotype data from 23andMe or Ancestry. Impute.me operated as a free community screening tool before 2022, while 23andMe+ Premium now bundles >25 PRS‑style reports for $199 (sale) or $268 list. These consumer options lack regulated lab pipelines and personalised counselling, so the lower cost estimate trades off clinical rigour.

Premium Panels & Multi‑Disease PRS Tests

Multi‑condition panels package ten or more diseases, genetic counselling and lifestyle coaching. Prices climb to $1,000–$1,700+, especially when oncology, cardiac and metabolic scores ship together. Provider Seonix Bio, for instance, prices its glaucoma “SightScore” saliva kit at $475.

Table 1: PRS Price Tiers

(Table total costs may swing 5–10 percent (give or take a few dollars).)

Cost‑Efficacy and Health Economics

Economic modelling from Finland lists the break‑even test price at €303 (≈ $330) for type 2 diabetes screening. An Allelica study projects $20 000–$120 000 in lifetime cardiac care savings when CAD‑PRS guides statin decisions. Health economist Prof Samuli Ripatti adds that “below the $300 mark, PRS returns net system value.” Such findings push payers to reconsider the scope of future coverage.

Factors Influencing PRS Test Pricing

Lab workflow, report interpretation, variant array density and ancestry modelling all shape the final price. CLIA‑certified labs add compliance overhead; ancestry‑adjusted algorithms demand extra analytics; and bundled genetic counselling can double the base fee. Consumer upload sites skip these layers, cutting both cost and reproducibility. Dr Jessica Hunter (ClinGen PRS Working Group) warns that “cheap tools without ancestry correction risk misleading prediction.”

To avoid surprise medical bills, check out our detailed cost guides on CBC, DUTCH, and NIPT tests alongside this PRS breakdown.

Health‑Economics & ROI Evidence

We found strong cost–benefit signals once a polygenic risk score (PRS) test drops below $330. A Canadian model by Kiflen et al. integrated a CAD‑PRS priced at $250 into first‑line statin algorithms; the incremental cost‑effectiveness ratio (ICER) fell under $50,000/QALY, the usual U.S. willingness‑to‑pay line, and the score became cost‑neutral as soon as the genotyping fee dipped below $200. This aligns with Allelica’s Finnish analysis showing population cardiac programs break even at €300 (~$330) per individual when downstream myocardial‑infarction care savings are counted.

International data strengthen the return‑on‑investment case. A 2024 Lancet Regional Health model covering six cancers in China reported an ICER of $14,930/QALY for PRS‑stratified screening versus age‑based screening, comfortably inside the country’s per‑capita GDP threshold for high‑value care. Sensitivity analysis showed the strategy stayed favorable while the test cost remained under €300.

Employer pilots add pragmatic evidence. A U.S. workplace prevention program that layered a CAD‑PRS on standard biometric checks projected lifetime savings of $21,000–$118,000 per high‑risk employee through earlier statin use and fewer catheterizations. In each scenario the score, not the drug bill, determined the break‑even point, confirming that the test price—not medication—controls ROI.

A 2025 systematic review across 18 economic evaluations found that 15 reached “high value” status once genotyping slid below $150 and prediction accuracy (AUC) exceeded 0.70. Programs with poorer discrimination or higher test fees failed to recover their outlays. The message is clear: keep the fee under $300, pair the result with actionable therapies, and the expense turns into a net health‑system gain.

Ancestry & Accuracy Limitations

Our data show that accuracy remains uneven across ancestry groups, pushing some providers to use costlier multi‑ethnic algorithms. The GPS‑Mult score for coronary disease, built on five continental cohorts, lifted prediction AUC from 0.63 to 0.71 in African‑ancestry samples but required denser variant arrays and extra computational layers, adding about $35 to the laboratory price tag. Allelica’s commercial pipeline quotes a 5–10 percent lab‑fee premium for its admixture‑aware models because of added imputation steps and recalibration against local incidence curves.

The ClinGen PRS Working Group warns that scores tuned only on European data inflate risk estimates by up to 40 percent in South‑Asian populations and under‑predict by a similar margin in West‑African groups. Such mis‑calibration leads to mis‑directed screening and wasted expense, undermining the very health prediction purpose. Geneticist Dr Jessica Hunter notes that “budget upload tools rarely disclose these drifts,” underlining why ancestry‑correction adds both cost and confidence.

GenomeWeb analysts report that providers now bundle ancestry‑adjusted interpretation as an optional $50 add‑on for consumer kits, while clinical labs embed the function in their base fee. The extra price buys tightened confidence intervals and fewer false alarms, yet many consumer sites still skip it entirely. The evidence suggests that spending a little more on ancestry‑fit analytics prevents far larger downstream health expenses.

Coverage & Reimbursement Trends

We found that most U.S. insurers classify PRS as “investigational,” leaving patients to absorb the full cost. Cigna’s May 2025 medical policy explicitly lists “polygenic risk score tests” under non‑covered services, and Blue Cross Blue Shield of Michigan flags multi‑condition panels as experimental, despite acknowledging rising clinical interest. Medicare has issued no national coverage determination; local contractors continue to deny claims, citing insufficient clinical‑utility evidence—effectively a blanket exclusion.

Employers are filling the gap. Endeavor Health’s PRS program, delivered through GenomicMD, prices a full clinical panel at $250 and bills it to wellness budgets rather than medical plans. Early adopters report high engagement but must manage privacy and data‑ownership clauses.

Table A – Current U.S. Reimbursement Snapshot (July 2025)

Until payer positions shift, insurance friction—not laboratory price—remains the main adoption barrier.

Regulatory & Clinical Oversight

We found a sharp divide between CLIA‑certified pipelines and open‑upload calculators. Labs such as Allelica, GenomicMD, and NorthShore run fully validated workflows, maintain duplicate QC, and issue physician‑signed reports—requirements that add roughly $75 to each test fee but guarantee chain‑of‑custody and reproducibility. By contrast, Impute.me—once the biggest free PRS site—went offline in July 2022, in part because it could not sustain compliance at scale.

CLIA oversight matters because it ties analytic validity to legal clinical utility. ClinGen’s latest summary states that “only CLIA‑verified scores should inform medical decision‑making,” noting assay drift in non‑certified uploads that changed absolute risk estimates by up to 8 percentage points in repeat analyses.

Hospitals accept CLIA reports into electronic records; DTC PDFs rarely meet that bar, blocking reimbursement appeals and malpractice protection. The extra regulatory expense buys consistency, which underpins any credible health prediction journey.

User Behaviors & Public Perception

Our data show awareness still lags. A February 2025 UK poll found only 11 percent of adults recognised the term “polygenic risk score,” yet once explained, 75 percent expressed interest—especially if the price stayed under £200. Cost therefore gates uptake more than curiosity.

Qualitative interviews with 52 primary‑care patients and 30 providers revealed mixed trust: many hailed the personalised prediction, but half of clinicians worried about false reassurance when scores lacked ancestry adjustment. Participants preferred a physician‑delivered interpretation even if that drove the expense from $40 to $250.

Real‑world stories illustrate the split. Some early adopters upload raw 23andMe data to free calculators to “get a number,” then pivot to a clinical lab when the risk looks high—incurring two fees rather than one. Others hold off until coverage appears, citing privacy or data‑ownership concerns. The pattern mirrors earlier genetic‑testing cycles: a tech‑savvy niche absorbs initial costs; mass uptake waits for payer endorsement and clear‑cut ROI evidence.

Real Patient Use Cases

•  Cardiac: A 42‑year‑old Floridian with family coronary history paid $250 for a hospital PRS, then changed diet and LDL goals.
  ● Oncology: Australian nurse Anna Wilson used Seonix Bio’s kit at $475 and now schedules earlier colonoscopies.
  ● Wellness: A California tech worker uploaded 23andMe data to a $40 indie calculator (attribue—attribute corrected) and shared the PDF with her trainer.

These snapshots show how expense, perceived risk, and provider trust steer decisions.

How to Save on PRS Testing Costs

You can lower net expense by timing purchases and using existing data:

• Upload raw genotypes to reputable PRS dashboards first; pay for clinical confirmation only if a high risk score emerges.
• Join academic pilot studies that waive the fee in exchange for follow‑up visits.

Potential Limitations and Hidden Costs

A PRS delivers a risk estimate, not a diagnosis. Without proper counselling, false reassurance or anxiety may trigger extra imaging or lab work. Some DTC platforms lock detailed score reports behind extra fees, and follow‑up lifestyle programs can add recurring price tags. Genetic counsellor Dr Muin Khoury cautions that downstream costs “often exceed the headline test figure.”

PRS vs Traditional Genetic Testing

Single‑gene BRCA or Lynch panels cost $200–$500 and usually gain insurance coverage if guidelines are met. PRS spans broader disease scope but currently demands personal payment, making it a companion rather than a replacement. Dr Jamie Craig emphasises that “PRS complements monogenic testing by flagging risk where no clear mutation exists.”

Expert Opinions & Recommendations

1. Dr Amit Khera, Cardiology, MGH: “A $250 cardiac PRS can steer statin starts and avoid later stent bills.”
2. Prof Jamie Craig, Ophthalmology, Flinders University: “Early glaucoma screening at $475 protects sight and lowers surgery demand.”
3. Nick Haan, CEO Seonix Bio: “Widespread PRS adoption will come once multi‑disease panels drop below $500.”
4. Prof Samuli Ripatti, University of Helsinki: “Our models show that a test priced under €300 pays for itself in population programs.”

Answers to Common Questions

Is the lab fee a one‑time payment?

Yes. DNA does not change, so a single PRS test covers lifelong genetic risk.

Can I use HSA funds to pay the cost?

Most U.S. administrators allow HSA reimbursement for medically ordered PRS, but not for pure consumer upload services.

Does ancestry affect the price?

No, but diverse ancestry modelling increases provider expenses, which can push price higher for some labs.

How long does a clinical PRS test take?

Turnaround averages three to four weeks from sample to score report.

Will insurance start covering PRS soon?

Large payers are reviewing data; coverage decisions could emerge once multi‑trial cost‑efficacy thresholds match the €300/$330 benchmark.